Table of Contents
Stockholm-based company Neko has raised $700 million in a Neko Health funding round, its Series C, as the firm pushes to take its futuristic medical scanning technology global. Neko has a mission to create a new system centered on early detection and disease prevention. The firm was founded by Daniel Ek, the co-founder of Spotify.
What This Neko Health Funding Round Means for Its Valuation
The $700 million funding round, led by Lightspeed Venture Partners, propels Neko Health to a valuation of nearly $7 billion. This represents a massive jump from its $1.7 billion valuation in early 2025, reflecting significant investor confidence in the company’s growth trajectory over the past year and a half.
What the Neko Health Scan Actually Offers
The Neko project is based on a futuristic 60-minute scan. Envision a contemporary, relaxing clinic with a body scan that takes about an hour and is completely non-invasive and radiation free. The scan is priced at £299 in the UK and 2,750 SEK in Sweden. The Neko scan is made possible with custom-made sensors and rapid blood testing, assessing cardiovascular, metabolic, and skin conditions while examining moles closely and looking for pre-diabetes and stroke risk factors.
How the Neko Health Experience Works for Patients
In just minutes, patients receive a detailed digital map of their body. Best of all, they can discuss the results right away with a face-to-face doctor, a solution to the stressful waiting periods common in the conventional medical system. More than 100,000 members have already used the service, a scale that likely helped attract investor interest in this Neko Health funding round.
High-Definition Upgrades and the In-House Advantage
Unlike many health companies, Neko owns every single part of its tech stack, building its own hardware and software in Sweden. Just last month, Neko rolled out its newest clinical devices: Derma-2, Echo-2, and Spectrum-2. These upgraded machines capture a much higher volume of biological signals across the skin, heart, and circulation, while adding instant body composition analysis and clinician wearable data reviews to the experience.
Notable Backers Behind This Neko Health Funding Round
The $700 million raised didn’t just come from venture capital. The startup saw funding from tech giants like Mark Zuckerberg and Priscilla Chan, along with celebrities like Maria Sharapova, Thierry Henry, will.i.am, and Tim Ferriss. Even Hollywood heavyweight Ari Emanuel and music executive Jimmy Iovine backed the round, reflecting the broad-based investor enthusiasm surrounding this Neko Health funding round.
Why Investors Are Excited
Investors are highly excited because Neko sits at the intersection of AI and is entering the U.S. market. After proving the model in Sweden and London, Neko is preparing for its biggest challenge yet, expansion into the American healthcare system.
What This Neko Health Funding Round Will Support in the US
Neko plans to open its first U.S. clinics in New York later this year. The startup has already received FDA clearance for several core products, an important regulatory milestone supporting this expansion effort. Ek, who stepped down as Spotify’s CEO earlier, is applying his classic international music-streaming expansion playbook to healthcare.
Acknowledging the Challenge Ahead
Admitting it’s difficult to go from Sweden to the UK, Ek said it will be ten times more difficult to deal with the complex U.S. healthcare landscape. Yet, there are more than 350,000 people on the waiting list, and the need is clear, suggesting strong consumer demand even amid the regulatory complexity Neko will face stateside.
Early Results Supporting the Neko Health Funding Round’s Ambitions
The platform is already showing measurable results. Early detection has translated into real-life improvements, with three out of four returning members keeping their flagged conditions safely under control, a data point that likely strengthened investor confidence heading into this Neko Health funding round.
What Comes Next
As Neko prepares to open its first U.S. clinics in New York later this year, the company’s ability to navigate American healthcare regulation, insurance dynamics, and consumer adoption will be closely watched as a test of whether its preventive, subscription-style scanning model can translate successfully beyond the European markets where it was first proven.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
